285 related articles for article (PubMed ID: 25109953)
1. Resistance acquisition to MDM2 inhibitors.
Cinatl J; Speidel D; Hardcastle I; Michaelis M
Biochem Soc Trans; 2014 Aug; 42(4):752-7. PubMed ID: 25109953
[TBL] [Abstract][Full Text] [Related]
2. Fortifying p53 - beyond Mdm2 inhibitors.
Sriraman A; Li Y; Dobbelstein M
Aging (Albany NY); 2016 Sep; 8(9):1836-1837. PubMed ID: 27688014
[No Abstract] [Full Text] [Related]
3. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
4. The role of p53 in cancer drug resistance and targeted chemotherapy.
Hientz K; Mohr A; Bhakta-Guha D; Efferth T
Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
[TBL] [Abstract][Full Text] [Related]
5. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.
Wang W; Hu Y
Med Res Rev; 2012 Nov; 32(6):1159-96. PubMed ID: 23059763
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
Gupta A; Shah K; Oza MJ; Behl T
Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
[TBL] [Abstract][Full Text] [Related]
7. Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).
Weber L
Expert Opin Ther Pat; 2010 Feb; 20(2):179-91. PubMed ID: 20100001
[TBL] [Abstract][Full Text] [Related]
8. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.
Lauria A; Tutone M; Ippolito M; Pantano L; Almerico AM
Curr Med Chem; 2010; 17(28):3142-54. PubMed ID: 20666726
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule inhibitors of MDM2 as new anticancer therapeutics.
Dickens MP; Fitzgerald R; Fischer PM
Semin Cancer Biol; 2010 Feb; 20(1):10-8. PubMed ID: 19897042
[TBL] [Abstract][Full Text] [Related]
10. Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.
Wang S; Zhao Y; Aguilar A; Bernard D; Yang CY
Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28270530
[TBL] [Abstract][Full Text] [Related]
11. p53-Mdm2 inhibitors: patent review (2009 - 2010).
Kamal A; Mohammed AA; Shaik TB
Expert Opin Ther Pat; 2012 Feb; 22(2):95-105. PubMed ID: 22316395
[TBL] [Abstract][Full Text] [Related]
12. Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present).
Zak K; Pecak A; Rys B; Wladyka B; Dömling A; Weber L; Holak TA; Dubin G
Expert Opin Ther Pat; 2013 Apr; 23(4):425-48. PubMed ID: 23374098
[TBL] [Abstract][Full Text] [Related]
13. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.
Shangary S; Wang S
Annu Rev Pharmacol Toxicol; 2009; 49():223-41. PubMed ID: 18834305
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
Zhao Y; Aguilar A; Bernard D; Wang S
J Med Chem; 2015 Feb; 58(3):1038-52. PubMed ID: 25396320
[TBL] [Abstract][Full Text] [Related]
16. FOLICation: engineering approved drugs as potential p53-MDM2 interaction inhibitors for cancer therapy.
Patil SP
Med Hypotheses; 2013 Dec; 81(6):1104-7. PubMed ID: 24210632
[TBL] [Abstract][Full Text] [Related]
17. Small molecule inhibitors of the p53-MDM2.
Hu CQ; Hu YZ
Curr Med Chem; 2008; 15(17):1720-30. PubMed ID: 18673221
[TBL] [Abstract][Full Text] [Related]
18. MDM2 inhibitors for pancreatic cancer therapy.
Azmi AS; Philip PA; Almhanna K; Beck FW; Sarkar FH; Mohammad RM
Mini Rev Med Chem; 2010 Jun; 10(6):518-26. PubMed ID: 20377522
[TBL] [Abstract][Full Text] [Related]
19. MDM2 inhibitors for cancer therapy.
Vassilev LT
Trends Mol Med; 2007 Jan; 13(1):23-31. PubMed ID: 17126603
[TBL] [Abstract][Full Text] [Related]
20. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]